Peptides are short chain of amino acids linked by peptide bonds. Usually they contain less than 50 amino acids. Natural cardiovascular peptides such as ANP and BNP are hormones of cardiac origin that play an important role in the regulation of cardiovascular homeostasis. Cardiovascular peptides are predominantly produced in heart, although many other tissues produced it but in amounts inadequate to induce any physiological effects. Advancement in biotechnology and pharmaceutical sciences has enable researchers to modify or mimic naturally occurring peptide for diverse therapeutic uses. One such example is Nesiritide, recombinant form of the 32 amino acid human B-type natriuretic peptide. Cardiovascular peptides are used in primarily to treat or avoid acute myocardial infarction, Coronary Ischemia, hypertension, Cardio metabolic Disease, heart failure, peripheral vascular diseases, and hematologic diseases.
Browse Report With Full TOC At : http://www.transparencymarketresearch.com/cardiovascular-peptides-market.html
Increasing prevalence of cardiovascular diseases obesity, sedentary lifestyle, serious side effects associated with currently available cardiovascular products and high risk linked with surgical procedures are some major factors driving the cardiovascular peptides market growth. As per the World Health Organization (WHO) statistics on cardiovascular diseases, approximately 17.3 million people died from cardiovascular diseases in 2008, accounting for nearly 30% of all global deaths. The WHO further states that the number of global deaths by cardiovascular diseases is expected to reach 30 million by 2030. Concerted efforts in research and development by pharmaceutical companies and extensive research collaborations would help them gain core competencies in this market. Big pharmaceutical companies such as Eli Lilly & Company, Novo Nordisk, Novartis AG, and Bristol Myers Squibb (BMS) have invested huge money in research and development of...